Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • A Retrospective Analysis of <i...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
A Retrospective Analysis of <i>BCR-ABL1</i> Kinase Domain Mutations in the Frontline Drug Intolerant or Resistant Chronic Myeloid Leukemia Patients: An Indian Experience from a High-End Referral Laboratory

A Retrospective Analysis of <i>BCR-ABL1</i> Kinase Domain Mutations in the Frontline Drug Intolerant or Resistant Chronic Myeloid Leukemia Patients: An Indian Experience from a High-End Referral Laboratory

Bibliographic Details
Main Authors: Atreye Majumdar, Rahul Katara, Avshesh Mishra, Aastha Gupta, Deepak K. Sharma, Aman K. Srivastava, Shivani Sharma, Ankita Jaiswal, Mallika Dixit, Vipin Kumar, Sachin Kumar, Varun Kumar, Rahul Sharma, Sambit K. Mohanty
Format: Article
Language:English
Published: Thieme Medical and Scientific Publishers Pvt. Ltd. 2024-04-01
Series:South Asian Journal of Cancer
Subjects:
chronic myeloid leukemia
kinase domain mutations
BCR-ABL1
tyrosine kinase inhibitors
Sanger sequencing
therapy resistance
Online Access:http://www.thieme-connect.de/DOI/DOI?10.1055/s-0042-1757911
  • Holdings
  • Description
  • Similar Items
  • Staff View

Internet

http://www.thieme-connect.de/DOI/DOI?10.1055/s-0042-1757911

Similar Items

  • BCR-ABL kinase domain mutations in CML patients, experience from a tertiary care center in North India
    by: Akhilesh S, et al.
    Published: (2024-01-01)
  • A Small Molecule Inhibitor, OGP46, Is Effective against Imatinib-Resistant BCR-ABL Mutations via the BCR-ABL/JAK-STAT Pathway
    by: Liuya Wei, et al.
    Published: (2020-09-01)
  • Combined targeting of GPX4 and BCR-ABL tyrosine kinase selectively compromises BCR-ABL+ leukemia stem cells
    by: Chengwu Zeng, et al.
    Published: (2024-10-01)
  • Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I
    by: Mian Afsar, et al.
    Published: (2012-09-01)
  • Unveiling the nephrotoxic profile of BCR‐ABL tyrosine kinase inhibitors: A real‐world experience in Africa
    by: Zekarias Seifu Ayalew, et al.
    Published: (2024-08-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs